SR One Capital Management LP Acquires 55,000 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

SR One Capital Management LP grew its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 14.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 430,330 shares of the company's stock after buying an additional 55,000 shares during the quarter. Oruka Therapeutics accounts for 2.0% of SR One Capital Management LP's investment portfolio, making the stock its 8th largest position. SR One Capital Management LP owned about 1.23% of Oruka Therapeutics worth $8,344,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Wellington Management Group LLP purchased a new stake in shares of Oruka Therapeutics during the third quarter worth $2,013,000. Geode Capital Management LLC acquired a new position in Oruka Therapeutics during the third quarter worth $343,000. Franklin Resources Inc. purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at $17,661,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Oruka Therapeutics during the 4th quarter valued at about $144,000. Finally, AlphaCentric Advisors LLC acquired a new stake in Oruka Therapeutics during the fourth quarter worth about $119,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Trading Up 7.1 %

ORKA traded up $0.66 during trading hours on Tuesday, hitting $9.96. 76,079 shares of the company's stock were exchanged, compared to its average volume of 237,409. The firm has a market cap of $372.95 million, a P/E ratio of -1.59 and a beta of 0.47. Oruka Therapeutics, Inc. has a 12-month low of $5.49 and a 12-month high of $31.13. The firm has a 50 day moving average of $10.10 and a 200 day moving average of $17.15.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.19. As a group, research analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Analyst Ratings Changes

ORKA has been the subject of several analyst reports. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research initiated coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price target for the company. Finally, Wedbush reaffirmed an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Oruka Therapeutics has a consensus rating of "Buy" and an average price target of $39.86.

Insider Buying and Selling at Oruka Therapeutics

In other news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the company's stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $11.44 per share, with a total value of $1,015,803.36. Following the transaction, the insider now owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. This trade represents a 2.19 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased 98,339 shares of company stock valued at $1,128,456 in the last quarter. Corporate insiders own 22.67% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.